![JAKAFI ruxolitinib](/img/default-banner.jpg)
- 28
- 35 674
JAKAFI ruxolitinib
United States
Приєднався 4 вер 2019
Welcome to the Jakafi (ruxolitinib) UA-cam channel.
Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
Jakafi is used to treat adults with certain types of myelofibrosis.
Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.
Jakafi is also used to treat adults and children 12 years of age and older with chronic GVHD who have taken one or two types of treatments and they did not work well enough.
Please see the links below for Important Safety Information and Prescribing Information for Jakafi.
Visit Jakafi.com to learn more.
Incyte and the Incyte logo are registered trademarks of Incyte. Jakafi and the Jakafi logo are registered trademarks of Incyte.
© 2024, Incyte. MAT-JAK-05154 07/24
Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
Jakafi is used to treat adults with certain types of myelofibrosis.
Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.
Jakafi is also used to treat adults and children 12 years of age and older with chronic GVHD who have taken one or two types of treatments and they did not work well enough.
Please see the links below for Important Safety Information and Prescribing Information for Jakafi.
Visit Jakafi.com to learn more.
Incyte and the Incyte logo are registered trademarks of Incyte. Jakafi and the Jakafi logo are registered trademarks of Incyte.
© 2024, Incyte. MAT-JAK-05154 07/24
From PV to Possible
Have you noticed your polycythemia vera (PV) impacting the things you enjoy doing? You may blame the way you feel on getting older, but it could mean that your PV is getting worse. It's time to help take control of your PV and discover your path to possible. Talk to your doctor to find out if Jakafi® (ruxolitinib) is right for you.
This video is intended for informational use only and is not designed to replace the medical advice of your healthcare professional. Jakafi is a prescription medicine used to treat adults with PV who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
In a clinical trial of patients with PV, Jakafi kept the volume of red blood cells under control, reducing the need for phlebotomy, and reduced spleen size.
Selected Safety Information
Jakafi can cause serious side effects, including low blood counts and infection. Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of myelofibrosis and PV include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects.
To learn more about these and other risks, please read the Important Safety Information at www.jakafi.com/polycythemia-vera/.
Please see the Full Prescribing Information www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to lncyte Medical Information at 1-855-463-3463.
For information, support, and resources about Jakafi, visit www.jakafi.com/register-forresources.
Jakafi® (ruxolitinib) is available in 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg tablets.
Jakafi, the Jakafi logo, Incyte, and the Incyte logo are registered trademarks of Incyte.
© 2024, Incyte. MAT-JAK-04970 04/24
This video is intended for informational use only and is not designed to replace the medical advice of your healthcare professional. Jakafi is a prescription medicine used to treat adults with PV who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
In a clinical trial of patients with PV, Jakafi kept the volume of red blood cells under control, reducing the need for phlebotomy, and reduced spleen size.
Selected Safety Information
Jakafi can cause serious side effects, including low blood counts and infection. Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of myelofibrosis and PV include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects.
To learn more about these and other risks, please read the Important Safety Information at www.jakafi.com/polycythemia-vera/.
Please see the Full Prescribing Information www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to lncyte Medical Information at 1-855-463-3463.
For information, support, and resources about Jakafi, visit www.jakafi.com/register-forresources.
Jakafi® (ruxolitinib) is available in 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg tablets.
Jakafi, the Jakafi logo, Incyte, and the Incyte logo are registered trademarks of Incyte.
© 2024, Incyte. MAT-JAK-04970 04/24
Переглядів: 1 633
Відео
Watch Oncology Clinical Nurse Educators and Real Patients Speak About Jakafi® (ruxolitinib)
Переглядів 1,5 тис.Рік тому
For people living with a rare, chronic blood cancer, finding the right treatment option can be challenging. Listen to people living with polycythemia vera (PV) and certain types of myelofibrosis (MF) taking Jakafi discuss their experiences, providing special insight and information on the everyday issues and important obstacles they face as individuals with rare diseases. This video also featur...
Connect With Patients and Caregivers Affected by PV or MF
Переглядів 337Рік тому
Connect with people affected by polycythemia vera (PV) or myelofibrosis (MF) through the Incyte Mentor Program or the Ambassadors for Jakafi® (ruxolitinib) program. The Mentor Program offers support for patients and caregivers while the Ambassadors for Jakafi program enables eligible patients taking Jakafi to share their stories of inspiration and hope. Watch the video to find out how to regist...
In The Purple Chair
Переглядів 4332 роки тому
Meet 4 inspiring individuals as they share their stories in a powerful patient education series called The Purple Chair. Get a glimpse into their journeys with polycythemia vera (PV) and intermediate or high-risk myelofibrosis (MF) as they find a path forward with Jakafi® (ruxolitinib). Register now for information, support, and resources about Jakafi. Visit www.Jakafi.com/register.aspx. Jakafi...
INDICATIONS AND IMPORTANT SAFETY INFORMATION for Jakafi® (ruxolitinib)
Переглядів 7402 роки тому
Indications and Usage Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it. Jakafi is used to treat adults with certain types of myelofibrosis. Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD)...
What Are the Effects of Jakafi® (ruxolitinib) in Clinical Trials?
Переглядів 6262 роки тому
Hematologist‐oncologist Gary Grad, MD, explains the results of two clinical studies that explored whether Jakafi® (ruxolitinib) reduced the size of enlarged spleens in adults with intermediate‐2 or highrisk myelofibrosis (MF). Dr. Grad explains what an enlarged spleen is and why it’s important for adults with MF to monitor the size of their spleen on a regular basis. This video is intended for ...
The Purple Chair S1:E5 We Are Not Alone | Jakafi® (ruxolitinib)
Переглядів 2432 роки тому
#InThePurpleChair Episode 5 explores the power of connecting with others who live with the same condition. Hear Chuck, Donna, Mark, and Tami describe the difference it made when they found support. Learn why it's important for them to share their stories of hope and encouragement with other patients. Jakafi® (ruxolitinib) is a prescription medicine used to treat adults with polycythemia vera wh...
The Purple Chair S1:E4 Reflecting on the Possibilities | Jakafi® (ruxolitinib)
Переглядів 3682 роки тому
In Episode 4 of The Purple Chair series, patients change their perspectives after exploring treatment possibilities for polycythemia vera (PV) or intermediate or high-risk myelofibrosis (MF) with their Healthcare Professionals. Watch Chuck, Donna, Mark, and Tami share the experiences that encouraged them to talk about what could be possible with Jakafi® (ruxolitinib). Jakafi is a prescription m...
The Purple Chair S1:E3 Discovering the Power of Partnership | Jakafi® (ruxolitinib)
Переглядів 2692 роки тому
The third episode of The Purple Chair series highlights the importance of finding the right healthcare partners to manage your polycythemia vera (PV) or intermediate or high-risk myelofibrosis (MF). Watch as Chuck, Donna, Mark, and Tami reveal how Healthcare Professionals experienced in PV and MF made a meaningful difference in their care. Jakafi® (ruxolitinib) is a prescription medicine used t...
The Purple Chair S1:E2 Finding a Path Forward | Jakafi® (ruxolitinib)
Переглядів 3512 роки тому
In the second episode of The Purple Chair series, 4 patients living with polycythemia vera (PV) or intermediate or high-risk myelofibrosis (MF) describe the events that convinced them to become their own health advocates. Listen as Chuck, Donna, Mark, and Tami discuss what empowered their self-advocacy and how it helped them find a path forward. Jakafi® (ruxolitinib) is a prescription medicine ...
The Purple Chair S1:E1 How Our Journeys Began | Jakafi® (ruxolitinib)
Переглядів 5582 роки тому
Watch The Purple Chair and see how it could feel when you have been diagnosed with a rare, chronic blood cancer. Take a look as Chuck, Donna, Mark, and Tami share the beginning of their journeys with polycythemia vera (PV) or intermediate or high-risk myelofibrosis (MF). Hear about their very first experiences and how they began to find a path to possible. Jakafi® (ruxolitinib) is a prescriptio...
Donna’s Path to Possible With Jakafi® (ruxolitinib)
Переглядів 1,2 тис.2 роки тому
Donna was concerned when her flourishing career as a motivational speaker was interrupted by an unexpected decline in her health. After blood tests showed that her platelet count and hematocrit were abnormally high, Donna was diagnosed with a rare, chronic blood cancer called polycythemia vera (PV). Her oncologist prescribed hydroxyurea (HU), but Donna found she could not tolerate it. She was h...
How does Jakafi® (ruxolitinib) work?
Переглядів 4 тис.2 роки тому
Hear from an expert-learn how Jakafi (ruxolitinib) may help reduce the abnormal production of blood cells. Watch this video for a close-up look at how Jakafi works to affect overactive signaling, blood counts, and more. Jakafi® (ruxolitinib) is used to treat adults with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythem...
A Targeted Therapy for Myelofibrosis
Переглядів 2232 роки тому
Read below for Selected Safety Information. Hematologist-oncologist Gary Grad, MD explains how a targeted therapy called Jakafi® (ruxolitinib) acts in the body to help treat adults with intermediate- or high-risk myelofibrosis (MF). Jakafi is the first targeted therapy approved by the Food and Drug Administration for the treatment of these patients. Myelofibrosis is a rare, chronic blood cancer...
What Are the Common Side Effects of Jakafi® (ruxolitinib)?
Переглядів 3,5 тис.2 роки тому
Read below for Selected Safety Information. In this video, hematologist-oncologist Gary Grad, MD, talks about the most common side effects of a prescription medicine called Jakafi® (ruxolitinib). Dr Grad also describes which symptoms or developments patients should report to their Healthcare Professionals. He explains why Healthcare Professionals monitor patient blood counts during treatment wi...
How Long Should Patients Take Jakafi® (ruxolitinib)?
Переглядів 2,7 тис.2 роки тому
How Long Should Patients Take Jakafi® (ruxolitinib)?
How Do I Know If Hydroxyurea is Not Right for Me?
Переглядів 6 тис.2 роки тому
How Do I Know If Hydroxyurea is Not Right for Me?
How Do I Take Jakafi® (ruxolitinib)?
Переглядів 1,1 тис.2 роки тому
How Do I Take Jakafi® (ruxolitinib)?
What Effects Has Jakafi® (ruxolitinib) Shown in Clinical Trials?
Переглядів 1672 роки тому
What Effects Has Jakafi® (ruxolitinib) Shown in Clinical Trials?
How Can Certain Risk Factors Help Me Understand My Myelofibrosis?
Переглядів 1012 роки тому
How Can Certain Risk Factors Help Me Understand My Myelofibrosis?
What Long-Term Data Are Available for Jakafi® (ruxolitinib)?
Переглядів 8132 роки тому
What Long-Term Data Are Available for Jakafi® (ruxolitinib)?
Exploring a Therapy Called Jakafi® (ruxolitinib)
Переглядів 3822 роки тому
Exploring a Therapy Called Jakafi® (ruxolitinib)
Rob’s Path to Possible With Jakafi® (ruxolitinib)
Переглядів 8702 роки тому
Rob’s Path to Possible With Jakafi® (ruxolitinib)
Polycythemia Vera, Spleen Size & You
Переглядів 6 тис.2 роки тому
Polycythemia Vera, Spleen Size & You
My journey with aGVHD: Suzanne’s story
Переглядів 912 роки тому
My journey with aGVHD: Suzanne’s story
Exploring the possibilities: Nick’s Journey
Переглядів 1052 роки тому
Exploring the possibilities: Nick’s Journey